Guardant Health announced that the “positive results” from the NILE study, a head-to-head comparison of the Guardant360 assay to standard-of-care tissue testing for the identification of guideline-recommended biomarkers in first-line advanced non-small cell lung cancer patients, have been published in Clinical Cancer Research. The study adds new data regarding Guardant360’s high concordance to tissue testing to the abstract that was highlighted before the AACR Annual Meeting. The study adds to a “growing body of literature” demonstrating that using Guardant360 first for genomic biomarker detection in advanced NSCLC can increase the number of patients tested for guideline-recommended biomarkers.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.